DE69624115D1 - Benzimidazol verbindungen - Google Patents

Benzimidazol verbindungen

Info

Publication number
DE69624115D1
DE69624115D1 DE69624115T DE69624115T DE69624115D1 DE 69624115 D1 DE69624115 D1 DE 69624115D1 DE 69624115 T DE69624115 T DE 69624115T DE 69624115 T DE69624115 T DE 69624115T DE 69624115 D1 DE69624115 D1 DE 69624115D1
Authority
DE
Germany
Prior art keywords
benzimidazole compounds
benzimidazole
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624115T
Other languages
English (en)
Other versions
DE69624115T2 (de
Inventor
John Griffin
Hilary Calvert
Jane Curtin
Richard Newell
Thomas Golding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle University Ventures Ltd
Original Assignee
Newcastle University Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515843.2A external-priority patent/GB9515843D0/en
Priority claimed from GBGB9611245.3A external-priority patent/GB9611245D0/en
Application filed by Newcastle University Ventures Ltd filed Critical Newcastle University Ventures Ltd
Application granted granted Critical
Publication of DE69624115D1 publication Critical patent/DE69624115D1/de
Publication of DE69624115T2 publication Critical patent/DE69624115T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
DE69624115T 1995-08-02 1996-07-30 Benzimidazol verbindungen Expired - Fee Related DE69624115T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9515843.2A GB9515843D0 (en) 1995-08-02 1995-08-02 Benzimidazole compounds
GBGB9611245.3A GB9611245D0 (en) 1996-05-30 1996-05-30 Benzimidazole compounds
PCT/GB1996/001832 WO1997004771A1 (en) 1995-08-02 1996-07-30 Benzimidazole compounds

Publications (2)

Publication Number Publication Date
DE69624115D1 true DE69624115D1 (de) 2002-11-07
DE69624115T2 DE69624115T2 (de) 2003-06-18

Family

ID=26307504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624115T Expired - Fee Related DE69624115T2 (de) 1995-08-02 1996-07-30 Benzimidazol verbindungen

Country Status (26)

Country Link
US (2) US6100283A (de)
EP (1) EP0841924B1 (de)
JP (1) JPH11510154A (de)
KR (1) KR100447539B1 (de)
CN (1) CN1159007C (de)
AP (1) AP866A (de)
AT (1) ATE225173T1 (de)
AU (1) AU714873B2 (de)
BR (1) BR9610051A (de)
CA (1) CA2225465A1 (de)
CZ (1) CZ30398A3 (de)
DE (1) DE69624115T2 (de)
DK (1) DK0841924T3 (de)
EA (1) EA000999B1 (de)
ES (1) ES2183004T3 (de)
HU (1) HUP9901092A3 (de)
IL (1) IL123147A (de)
MX (1) MX9800927A (de)
NO (1) NO317033B1 (de)
NZ (1) NZ313713A (de)
OA (1) OA10661A (de)
PL (1) PL324869A1 (de)
PT (1) PT841924E (de)
SK (1) SK13598A3 (de)
TR (1) TR199800127T1 (de)
WO (1) WO1997004771A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776291B1 (fr) * 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) * 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト ２−フェニルベンズイミダゾールおよび２−フェニルインドール、その製造方法ならびに使用
DK1133477T3 (da) * 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DE19916460B4 (de) * 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
EP1140936B1 (de) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclische inhibitoren von poly(adp-ribose) polymerasen
FR2788518B1 (fr) * 1999-01-14 2001-03-02 Centre Nat Rech Scient Nouveaux carbamates actives stables, leur procede de preparation et leur utilisation pour la preparation d'urees
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) * 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
ES2290115T3 (es) * 2000-02-01 2008-02-16 ABBOTT GMBH &amp; CO. KG Compuestos heterociclicos y su aplicacion como inhibidores de parp.
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
DE10201240A1 (de) * 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2004065370A1 (en) * 2003-01-23 2004-08-05 Crystalgenomics, Inc. Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof
JP4726235B2 (ja) * 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
EP1906948A4 (de) 2005-07-18 2010-03-17 Bipar Sciences Inc Krebsbehandlung
JP5221368B2 (ja) 2005-11-14 2013-06-26 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） Ｐａｒｐ活性のインヒビター及びその使用
JP5162465B2 (ja) 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
SI2338487T1 (sl) * 2006-01-17 2014-01-31 Abbott Laboratories Kombinacijska terapija z inhibitorji PARP
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20090275619A1 (en) * 2006-04-03 2009-11-05 BOUERES Julia Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors
MX2008014004A (es) 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292306A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US20090062268A1 (en) * 2007-08-27 2009-03-05 Lead Therapeutics, Inc. Novel inhibitors of poly(adp-ribose)polymerase (parp)
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2240466B1 (de) 2008-01-08 2015-07-29 Merck Sharp & Dohme Limited Pharmazeutisch akzeptable salze von 2-{4-?(3s)-piperidin-3- [l]phenyl} -2h-indazol-7-carboxamid
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
AR080443A1 (es) * 2010-03-04 2012-04-11 Bayer Cropscience Ag 2-amidobencimidazoles sustituidos con fluruoalquilo
CN102417483A (zh) * 2010-09-27 2012-04-18 中国药科大学 作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
EP2561759A1 (de) 2011-08-26 2013-02-27 Bayer Cropscience AG Fluoralkyl-substituierte 2-amidobenzimidazole und ihre Wirkung auf das Pflanzenwachstum
CN103130723B (zh) * 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102627610B (zh) * 2012-04-11 2014-06-25 江苏先声药物研究有限公司 一类苯并咪唑类衍生物及其应用
WO2014037340A1 (de) 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
CN107556288A (zh) * 2016-07-01 2018-01-09 山东大学齐鲁医院 一种治疗转移性肿瘤的药物化合物
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
AU2017355402A1 (en) 2016-11-02 2019-05-30 Health Research, Inc. Combination treatment with antibody-drug conjugates and PARP inhibitors
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
JP2024503380A (ja) 2021-01-08 2024-01-25 サイブレクサ ２，インコーポレイテッド コンジュゲート連結部分を調製するための方法
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
CN118027013A (zh) * 2024-01-17 2024-05-14 上海市第一人民医院 靶向多聚adp核糖聚合酶的生物活性光敏剂、制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1087561A (en) * 1963-02-16 1967-10-18 Fisons Pest Control Ltd Fluorinated benzimidazoles and compositions containing them
DE3346575A1 (de) * 1983-12-23 1985-07-04 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzimidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB8822483D0 (en) * 1988-09-24 1988-10-26 Medical Res Council Developments relating to mas oncogene
GB8904174D0 (en) * 1989-02-23 1989-04-05 British Bio Technology Compounds
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
WO1992005784A1 (en) * 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5216003A (en) * 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5735973A (en) * 1993-12-20 1998-04-07 Tamura Kaken Corporation Printed circuit board surface protective agent
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives

Also Published As

Publication number Publication date
NO980414L (no) 1998-04-02
JPH11510154A (ja) 1999-09-07
CN1195985A (zh) 1998-10-14
DK0841924T3 (da) 2003-02-10
PT841924E (pt) 2003-02-28
US6100283A (en) 2000-08-08
KR19990036086A (ko) 1999-05-25
ATE225173T1 (de) 2002-10-15
EP0841924B1 (de) 2002-10-02
NO980414D0 (no) 1998-01-30
IL123147A0 (en) 1998-09-24
HUP9901092A3 (en) 2001-11-28
DE69624115T2 (de) 2003-06-18
NO317033B1 (no) 2004-07-26
CZ30398A3 (cs) 1998-06-17
EA199800184A1 (ru) 1998-10-29
EP0841924A1 (de) 1998-05-20
NZ313713A (en) 2001-03-30
HUP9901092A2 (hu) 1999-07-28
PL324869A1 (en) 1998-06-22
US6310082B1 (en) 2001-10-30
AU714873B2 (en) 2000-01-13
AP866A (en) 2000-08-17
OA10661A (en) 2002-11-25
EA000999B1 (ru) 2000-08-28
CA2225465A1 (en) 1997-02-13
MX9800927A (es) 1998-10-31
AP9801183A0 (en) 1998-01-31
IL123147A (en) 2004-02-19
WO1997004771A1 (en) 1997-02-13
KR100447539B1 (ko) 2004-11-10
TR199800127T1 (xx) 1998-04-21
ES2183004T3 (es) 2003-03-16
SK13598A3 (en) 1998-06-03
BR9610051A (pt) 1999-12-21
AU6624096A (en) 1997-02-26
CN1159007C (zh) 2004-07-28

Similar Documents

Publication Publication Date Title
ATE225173T1 (de) Benzimidazol verbindungen
ATE208377T1 (de) Substituierte benzylaminopiperloin verbindungen
DE69525418D1 (de) Benzimidazol-derivate
DK0994890T3 (da) Benzimidazolderivater
ATE298739T1 (de) Calcylitische verbindungen
BR9612465A (pt) Compostos heterocíclicos
FI971234A7 (fi) Imidatsolijohdannainen
ATE208762T1 (de) Parasitizide verbindungen
NO932146L (no) Benzimidazolderivater
FI915148A7 (fi) Indol- och bensimidazolsubstituerade imidazol- och bensimidazolderivat.
DE69807397D1 (de) Triazinylaminostilben Verbindungen
BR9600251A (pt) Composto
DE69531522D1 (de) Heterozyklische Verbindungen
ATE225364T1 (de) Bromotiacumicin verbindungen
BR9604831A (pt) Derivados de benzimidazol
DE69621933D1 (de) Pestizide tris-oximino heterocyclische verbindungen
BR9601295A (pt) Composto
FI934343L (fi) Bensimidazoler, laekemedel innehaollande dessa foereningar samt foerfaranden foer deras framstaellning
DE69634183D1 (de) Substituierte Heterocyclen
DE59811182D1 (de) Heterocyclische Verbindungen
DE59609500D1 (de) Benzimidazol-isoindoleninfarbstoffe
BR9611576A (pt) Composto
FI960366A7 (fi) Uusia substituoituja bentsimidatsoleja
ID18956A (id) Senyawa-senyawa herbisida
NO955008D0 (no) Boresystem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: ZEITLER, VOLPERT, KANDLBINDER, 80539 MUENCHEN

8339 Ceased/non-payment of the annual fee